Zacks: Analysts Anticipate Genmab A/S (NASDAQ:GMAB) to Announce $0.08 EPS

Equities analysts expect Genmab A/S (NASDAQ:GMAB) to report earnings per share of $0.08 for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Genmab A/S’s earnings, with the lowest EPS estimate coming in at $0.06 and the highest estimate coming in at $0.10. Genmab A/S posted earnings per share of $0.76 during the same quarter last year, which would indicate a negative year over year growth rate of 89.5%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 11th.

According to Zacks, analysts expect that Genmab A/S will report full-year earnings of $0.57 per share for the current year, with EPS estimates ranging from $0.37 to $0.79. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.73 per share, with EPS estimates ranging from $0.59 to $0.98. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Genmab A/S.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.22. The business had revenue of $256.24 million for the quarter, compared to the consensus estimate of $214.90 million. Genmab A/S had a return on equity of 29.11% and a net margin of 51.35%.

Several research firms have weighed in on GMAB. TheStreet upgraded Genmab A/S from a “c” rating to a “b” rating in a research note on Monday, May 24th. SVB Leerink cut their target price on Genmab A/S from $38.00 to $36.00 and set a “market perform” rating for the company in a research note on Thursday, February 25th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Genmab A/S in a research note on Wednesday. Truist upped their target price on Genmab A/S from $42.00 to $47.00 in a research note on Thursday, February 25th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Genmab A/S in a research note on Friday, May 28th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. Genmab A/S currently has a consensus rating of “Hold” and a consensus price target of $42.13.

Large investors have recently made changes to their positions in the stock. San Francisco Sentry Investment Group CA bought a new position in Genmab A/S during the 4th quarter worth $32,000. JPMorgan Chase & Co. grew its holdings in Genmab A/S by 49.0% during the 4th quarter. JPMorgan Chase & Co. now owns 827 shares of the company’s stock worth $33,000 after acquiring an additional 272 shares during the period. Veriti Management LLC acquired a new stake in Genmab A/S during the 4th quarter worth about $42,000. Captrust Financial Advisors grew its holdings in Genmab A/S by 164.5% during the 1st quarter. Captrust Financial Advisors now owns 1,058 shares of the company’s stock worth $35,000 after acquiring an additional 658 shares during the period. Finally, Penserra Capital Management LLC grew its holdings in Genmab A/S by 192.1% during the 4th quarter. Penserra Capital Management LLC now owns 1,075 shares of the company’s stock worth $43,000 after acquiring an additional 707 shares during the period. 6.42% of the stock is owned by institutional investors and hedge funds.

NASDAQ:GMAB traded up $0.16 during trading hours on Friday, reaching $43.79. 18,852 shares of the company were exchanged, compared to its average volume of 543,409. The firm has a market capitalization of $28.74 billion, a P/E ratio of 33.56, a P/E/G ratio of 2.69 and a beta of 0.89. Genmab A/S has a 1-year low of $29.06 and a 1-year high of $44.83. The firm has a 50 day moving average of $37.45.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL.

Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.